{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:27:18Z","timestamp":1792643238832,"version":"4.5.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T00:00:00Z","timestamp":1573430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In renal studies, various outcome endpoints are used with variable definitions, making it nearly impossible to perform meta-analyses and deduce meaningful conclusions. Increasing attention is directed towards standardization of renal outcome reporting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A working group was formed to produce a unifying definition of renal outcomes that can be used by all investigators. We propose major adverse renal events (MARE) as the term for a standardized composite of hard renal outcomes. We discuss the components for inclusion in MARE from existing evidence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>MARE could include three to five items, considered relevant to patients and regulators. New onset of kidney injury, that is persistent albuminuria\/proteinuria and\/or decreasing glomerular filtration rate (GFR) &amp;lt;60\u2009ml\/min\/1.73\u2009m2, persistent signs of worsening kidney disease, development of end-stage kidney disease with estimated GFR &amp;lt;15\u2009ml\/min\/1.73\u2009m2 without or with initiation of kidney replacement therapy, and death from renal cause are core items of MARE. Additionally, patient reported outcomes should be reported in parallel to MARE as a standard set of primary (or secondary) endpoints in studies on kidney disease of diabetic, hypertensive-vascular, or other origin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>MARE as a reporting standard will enhance the ability to compare studies and thus, facilitate meaningful meta-analyses. This will result in standardized endpoints that should result in guideline improvement to better individualize care of patients with kidney disease.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ndt\/gfz212","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T11:16:15Z","timestamp":1570014975000},"page":"491-497","source":"Crossref","is-referenced-by-count":31,"title":["Major adverse renal events (MARE): a proposal to unify renal endpoints"],"prefix":"10.1093","volume":"36","author":[{"given":"Friedrich C","family":"Prischl","sequence":"first","affiliation":[{"name":"Department of Nephrology, 4th Department of Internal Medicine, Klinikum WelsGrieskirchen, Wels, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"Steno Diabetes Center Copenhagen, University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[{"name":"Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University Hospital, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,11]]},"reference":[{"key":"2021022209000784000_gfz212-B1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease\u2013Improving Global Outcomes (KDIGO) Controversies Conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"2021022209000784000_gfz212-B2","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.kint.2017.05.011","article-title":"The fragility of significant results underscores the need of larger randomized controlled trials in nephrology","volume":"92","author":"Shochet","year":"2017","journal-title":"Kidney Int"},{"key":"2021022209000784000_gfz212-B3","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.kint.2018.08.018","article-title":"Implementing core outcomes in kidney disease: report of the Standardized Outcomes in Nephrology (SONG) implementation workshop","volume":"94","author":"Tong","year":"2018","journal-title":"Kidney Int"},{"key":"2021022209000784000_gfz212-B4","year":"2017"},{"key":"2021022209000784000_gfz212-B5","first-page":"1268","article-title":"Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice","volume":"32","author":"Nistor","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2021022209000784000_gfz212-B6"},{"key":"2021022209000784000_gfz212-B7"},{"key":"2021022209000784000_gfz212-B8","first-page":"490","article-title":"Clinical trials end points for hemodialysis vascular access. Background, rationale, and definitions","volume-title":"Clin J Am Soc Nephrol","author":"Shenoy","year":"2018"},{"key":"2021022209000784000_gfz212-B9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2215\/CJN.11531116","article-title":"Definitions and end points for interventional studies for arteriovenous dialysis access","volume":"13","author":"Beathard","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B10","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.2337\/dc19-S011","article-title":"Microvascular complications and foot care: standards of medical care in diabetes\u20142019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"key":"2021022209000784000_gfz212-B11","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00508-018-1425-x","article-title":"[Diabetic kidney disease (Update 2019). Position paper of the Austrian Diabetes Association and the Austrian Society of Nephrology]","volume":"131","author":"Sourij","year":"2019","journal-title":"Wien Klin Wochenschr"},{"key":"2021022209000784000_gfz212-B12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B14","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","article-title":"Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies","volume":"7","author":"Coresh","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021022209000784000_gfz212-B15","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.ekir.2018.04.008","article-title":"Renal outcomes of antidiabetic treatment options in type-2 diabetes\u2014a proposed MARE definition","volume":"3","author":"Prischl","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2021022209000784000_gfz212-B16","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.2215\/CJN.12011116","article-title":"Recommended trial end points for dialysis catheters","volume":"13","author":"Allon","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2215\/CJN.02900317","article-title":"FDA regulatory perspectives for studies on hemodialysis vascular access","volume":"13","author":"Hurst","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B19","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1681\/ASN.2017020148","article-title":"Effects of intensive BP control in CKD","volume":"28","author":"Cheung","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B20","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.2215\/CJN.09590916","article-title":"Is chronic dialysis the right hard renal end point to evaluate renoprotective drug effects?","volume":"12","author":"Weldegiorgis","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/clpt.2011.195","article-title":"Developing a valid patient-reported outcome measure","volume":"90","author":"Rothrock","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"2021022209000784000_gfz212-B22"},{"key":"2021022209000784000_gfz212-B23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","article-title":"The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection","volume":"30","author":"Ware","year":"1992","journal-title":"Med Care"},{"key":"2021022209000784000_gfz212-B24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00451725","article-title":"Development of the Kidney Disease Quality of Life (KDQOL) instrument","volume":"3","author":"Hays","year":"1994","journal-title":"Qual Life Res"},{"key":"2021022209000784000_gfz212-B25","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1053\/j.ajkd.2017.07.020","article-title":"Psychometric properties of the kidney disease quality of life 36-item short-form survey (KDQOL-36) in the United States","volume":"71","author":"Peipert","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2021022209000784000_gfz212-B26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.13063\/2327-9214.1015","article-title":"Advances in patient reported outcomes: the NIH PROMIS measures","volume":"1","author":"Broderick","year":"2013","journal-title":"eGEMs"},{"key":"2021022209000784000_gfz212-B27","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/ki.2013.248","article-title":"Role of Nrf2 in protection against acute kidney injury","volume":"84","author":"Shelton","year":"2013","journal-title":"Kidney Int"},{"key":"2021022209000784000_gfz212-B28","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1056\/NEJMoa1306033","article-title":"Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease","volume":"369","author":"de Zeeuw","year":"2013","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B29","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B30","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000490007","article-title":"Tubular recovery after acute kidney injury","volume":"140","author":"Fattah","year":"2018","journal-title":"Nephron"},{"key":"2021022209000784000_gfz212-B31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1093\/ndt\/gfy036","article-title":"The impact of outpatient acute kidney injury on mortality and chronic kidney disease: a retrospective cohort study","volume":"34","author":"Leither","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2021022209000784000_gfz212-B32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s10157-018-1588-9","article-title":"Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on beta2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis \u2013 Oshima Award Address 2016","volume":"23","author":"Yamamoto","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"2021022209000784000_gfz212-B33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.semnephrol.2018.02.003","article-title":"Cardiovascular disease and diabetic kidney disease","volume":"38","author":"Maqbool","year":"2018","journal-title":"Semin Nephrol"},{"key":"2021022209000784000_gfz212-B34","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1681\/ASN.2019010007","article-title":"GFR slope as a surrogate endpoint for kidney disease progression in clinical trials: a meta-analysis of treatment effects of randomized controlled trials","volume":"30","author":"Inker","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B35","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical practice guidelines for diabetes and chronic kidney disease: 2012 update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2021022209000784000_gfz212-B36","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"2021022209000784000_gfz212-B37","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2215\/CJN.06200518","article-title":"Long-term effects of intensive glycemic and blood pressure control and fenofibrate use on kidney outcomes","volume":"13","author":"Mottl","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B38","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2215\/CJN.11370918","article-title":"ACCORDION: ensuring that we hear the music clearly","volume":"13","author":"Wong","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1053\/j.ajkd.2018.04.023","article-title":"Chronic kidney disease biomarkers consortium investigators. Biological variability of estimated GFR and albuminuria in CKD","volume":"72","author":"Waikar","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2021022209000784000_gfz212-B40","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an endpoint for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2021022209000784000_gfz212-B41","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1681\/ASN.2018010103","article-title":"Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial","volume":"29","author":"Wanner","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B42","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1001\/jama.2014.6634","article-title":"Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality","volume":"311","author":"Coresh","year":"2014","journal-title":"JAMA"},{"key":"2021022209000784000_gfz212-B43","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s001250050616","article-title":"Patterns of renal injury in NIDDM patients with microalbuminuria","volume":"39","author":"Fioretto","year":"1996","journal-title":"Diabetologia"},{"key":"2021022209000784000_gfz212-B44","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Renal Pathology Society: pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B45","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1681\/ASN.2017020192","article-title":"Segmental sclerosis and extracapillary hypercellularity predict diabetic ESRD","volume":"29","author":"Mottl","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B46","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.diabres.2012.03.016","article-title":"Clinical implications of pathologic diagnosis and classification for diabetic nephropathy","volume":"97","author":"Oh","year":"2012","journal-title":"Diabetes Res Clin Pract"},{"key":"2021022209000784000_gfz212-B47","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/ndt\/gfu250","article-title":"Renal histologic changes and the outcome in patients with diabetic nephropathy","volume":"30","author":"An","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2021022209000784000_gfz212-B48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/dmrr.2633","article-title":"Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic patients","volume":"31","author":"Mise","year":"2015","journal-title":"Diabetes Metab Res Rev"},{"key":"2021022209000784000_gfz212-B49","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1111\/dom.12936","article-title":"The albuminuria-lowering response to dapagliflozin is variable and reproducible among individual patients","volume":"19","author":"Petrykiv","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2021022209000784000_gfz212-B50","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/ndt\/gfv429","article-title":"Individual long-term albuminuria exposure during angiotensin receptor blocker therapy is the optimal predictor for renal outcome","volume":"31","author":"Kr\u00f6pelin","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2021022209000784000_gfz212-B51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/bmj.304.6823.339","article-title":"Renal protective effect of enalapril in diabetic nephropathy","volume":"304","author":"Bjorck","year":"1992","journal-title":"Br Med J"},{"key":"2021022209000784000_gfz212-B52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B53","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1681\/ASN.V191087","article-title":"Assessing the progression of renal disease in clinical studies: effects of duration of follow-up and regression to the mean. Modification of Diet in Renal Disease (MDRD) Study Group","volume":"1","author":"Levey","year":"1991","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B54","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1681\/ASN.2015111230","article-title":"Anti-TGF-\u03b21 antibody therapy in patients with diabetic nephropathy","volume":"28","author":"Voelker","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B55","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"2021022209000784000_gfz212-B56","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B57","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1681\/ASN.2008030292","article-title":"First morning voids are more reliable than spot urine samples to assess microalbuminuria","volume":"20","author":"Witte","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2021022209000784000_gfz212-B58","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.kint.2016.10.046","article-title":"Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes","volume":"91","author":"Krolewski","year":"2017","journal-title":"Kidney Int"},{"key":"2021022209000784000_gfz212-B59","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/j.ajkd.2018.07.015","article-title":"Effects of intensive blood pressure lowering on kidney tubule injury in CKD: a longitudinal subgroup analysis in SPRINT","volume":"73","author":"Malhortra","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2021022209000784000_gfz212-B60","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1001\/archinte.165.8.947","article-title":"The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension","volume":"165","author":"Lea","year":"2005","journal-title":"Arch Intern Med"},{"key":"2021022209000784000_gfz212-B61","first-page":"388","article-title":"Albuminuria reduction and nephropathy progression","volume":"10","author":"Bakris","year":"2008","journal-title":"Curr Hypertens Rep"},{"key":"2021022209000784000_gfz212-B62","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"2021022209000784000_gfz212-B63","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"2021022209000784000_gfz212-B64","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2021022209000784000_gfz212-B65","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"2021022209000784000_gfz212-B66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"Arch Intern Med"},{"key":"2021022209000784000_gfz212-B67","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1159\/000343453","article-title":"Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success","volume":"36","author":"Hirsch","year":"2012","journal-title":"Am J Nephrol"},{"key":"2021022209000784000_gfz212-B68","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.ajkd.2013.03.018","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for management of blood pressure in CKD","volume":"62","author":"Taler","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"2021022209000784000_gfz212-B69","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1093\/ndt\/9.8.1097","article-title":"Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus","volume":"9","author":"Biesenbach","year":"1994","journal-title":"Nephrol Dial Transplant"},{"key":"2021022209000784000_gfz212-B70","doi-asserted-by":"crossref","first-page":"664","DOI":"10.2215\/CJN.12201018","article-title":"Major adverse kidney events in pediatric sepsis","volume":"14","author":"Weiss","year":"2019","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/3\/491\/36327660\/gfz212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/36\/3\/491\/36327660\/gfz212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T20:18:06Z","timestamp":1664569086000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/3\/491\/5620405"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,11]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,11,11]]},"published-print":{"date-parts":[[2021,2,20]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfz212","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,3,1]]},"published":{"date-parts":[[2019,11,11]]}}}